Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAT-1: Fluzoparib and Apatinib Maintenance in Ovarian Cancer
NCT06539091Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of fluzoparib and Rivoceranib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-Free Survival at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06539091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539091.